Non-alcoholic fatty liver disease: Factors associated with its presence and onset

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue S4, 2013, Pages 71-78

  Miyake, Teruki ^a   Kumagi, Teru ^a   Furukawa, Shinya ^a   Tokumoto, Yoshio ^a   Hirooka, Masashi ^a   Abe, Masanori ^a   Hiasa, Yoichi ^a   Matsuura, Bunzo ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood tests; Non alcoholic fatty liver disease; Physical measurements; Predictive factors; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; TRIACYLGLYCEROL; URIC ACID;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CHRONIC LIVER DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FATTY LIVER; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYPERURICEMIA; INFLAMMATION; INSULIN RESISTANCE; LABORATORY TEST; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER DISEASE; LIVER FUNCTION TEST; MEDICAL PRACTICE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

BLOOD TESTS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSICAL MEASUREMENTS; PREDICTIVE FACTORS; RISK FACTORS;

BILIRUBIN; BIOLOGICAL MARKERS; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FATTY LIVER; FERRITINS; FORECASTING; HEMOGLOBINS; HUMANS; INSULIN RESISTANCE; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84897664326     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12251     Document Type: Article

References (49)

1. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
2. Marchesini G, Brizi M, Bianchi G etal. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
3. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
4. Yoshioka Y, Hashimoto E, Yatsuji S etal. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J. Gastroenterol. 2004; 39: 1215-1218.
5. Shimada M, Hashimoto E, Taniai M etal. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37: 154-160.
6. Hamaguchi M, Kojima T, Takeda N etal. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 2007; 13: 1579-1584.
7. Bae JC, Rhee EJ, Lee WY etal. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011; 34: 727-729.
8. Lazo M, Hernaez R, Bonekamp S etal. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891.
9. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J. Gastroenterol. 2011; 46 (Suppl. 1): S63-S69.
10. Bhala N, Angulo P, van der Poorten D etal. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216.
11. Tokunaga K, Matsuzawa Y, Kotani K etal. Ideal body weight estimated from the body mass index with the lowest morbidity. Int. J. Obes. 1991; 15: 1-5.
12. Miyake T, Kumagi T, Hirooka M etal. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J. Gastroenterol. 2012; 47: 696-703.
13. Miyake T, Kumagi T, Furukawa S etal. Reply to the letter by Lai etal. regarding "Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal study." J. Gastroenterol. 2013; 48: 550-551.
14. Eguchi Y, Hyogo H, Ono M etal. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 2012; 47: 586-595.
15. Kwak MS, Kim D, Chung GE etal. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2012; 18: 383-390.
16. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol. 2009; 50: 1029-1034.
17. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 2013; 62: 392-399.
18. Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J. Korean Med. Sci. 2011; 26: 386-391.
19. Kuo CF, Yu KH, Luo SF etal. Gout and risk of non-alcoholic fatty liver disease. Scand. J. Rheumatol. 2010; 39: 466-471.
20. Ma H, Xu C, Xu L, Yu C, Miao M, Li Y. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol. 2013; 13: 3.
21. Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers. Nutr. Metab. Cardiovasc. Dis. 2013; pii: S0939-4753(13)00009-4. [Epub ahead of print]. doi: 10.1016/j.numecd.2013.01.006
22. Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am. J. Epidemiol. 2001; 154: 758-764.
23. Miyake T, Kumagi T, Hirooka M etal. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J. Gastroenterol. 2013; 48: 413-422.
24. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin. Chem. 2007; 53: 686-692.
25. Chang Y, Ryu S, Zhang Y etal. A cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers. PLoS ONE 2012; 7: e37241.
26. Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS ONE 2010; 5: e11578.
27. Lee JW, Cho YK, Ryan M etal. Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut. Liver 2010; 4: 378-383.
28. Hamaguchi M, Kojima T, Takeda N etal. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 722-728.
29. Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J. Hepatol. 2011; 56: 241-247.
30. Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism 2012; 61: 1182-1188.
31. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and investigation strategies. Lancet 2004; 363: 157-163.
32. Prati D, Taioli E, Zanella A etal. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 1-10.
33. Lee JK, Shim JH, Lee HC etal. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010; 51: 1577-1583.
34. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983.
35. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046.
36. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl Acad. Sci. U. S. A. 2002; 99: 16093-16098.
37. Lin LY, Kuo HK, Hwang JJ etal. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009; 203: 563-568.
38. Tanaka M, Fukui M, Tomiyasu K etal. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 2009; 206: 287-291.
39. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 166-172.
40. Cheriyath P, Gorrepati VS, Peters I etal. High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES data from 1999-2006. J. Clin. Med. Res. 2010; 2: 201-206.
41. Hjelkrem M, Morales A, Williams CD, Harrison SA. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). Aliment. Pharmacol. Ther. 2012; 35: 1416-1423.
42. Chen CH, Huang MH, Yang JC etal. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J. Clin. Gastroenterol. 2006; 40: 745-752.
43. Sung KC, Kim BS, Cho YK etal. Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. BMC Gastroenterol. 2012; 12: 84.
44. Brown MS, Goldstein JL. Selective vs. total insulin resistance: a pathogenic paradox. Cell Metab. 2008; 7: 95-96.
45. Nagasawa N, Tamakoshi K, Yatsuya H etal. Association of white blood cell count and clustered components of metabolic syndrome in Japanese men. Circ. J. 2004; 68: 892-897.
46. Lee YJ, Lee HR, Shim JY, Moon BS, Lee JH, Kim JK. Relationship between white blood cell count and nonalcoholic fatty liver disease. Dig. Liver Dis. 2010; 42: 888-894.
47. Valenti L, Fracanzani AL, Bugianesi E etal. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010; 138: 905-912.
48. Bedogni G, Bellentani S, Miglioli L etal. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33.
49. Lee JH, Kim D, Kim HJ etal. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010; 42: 503-508.